Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781283 | 0.89 | PPARA (0.60) | PPARAHPGDPPARGPPARDRAB9A | |
| SCHEMBL6781085 | 0.84 | PPARA (0.46) | PPARAPPARGPPARD | |
| SCHEMBL6780961 | 0.84 | PPARA (0.56) | PPARAPPARGPPARD | |
| Hydrochloric Acid SCHEMBL6784848 | 0.84 | PPARA (0.49) | PPARAHPGDPPARGPPARDTSHR | |
| SCHEMBL6778713 | 0.81 | PPARA (0.43) | PPARAHPGDPPARGPPARDTSHR | |
| SCHEMBL6777896 | 0.81 | PPARA (0.58) | PPARAHPGDPPARGPPARDMEN1 | |
| SCHEMBL6780090 | 0.81 | PPARA (0.42) | PPARAHPGDPPARGPPARDRAB9A | |
| SCHEMBL4884303 | 0.79 | TBXAS1 (0.38) | PPARAPPARGPPARDRAB9ACYP3A4 | |
| SCHEMBL6780864 | 0.79 | PPARA (0.43) | PPARAPPARGPPARD | |
| SCHEMBL6781086 | 0.79 | PPARA (0.41) | PPARAPPARGPPARDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176445-A1 | Propionic acid derivatives | BAYER PHARMACEUTICALS CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6750236-B2 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20030187041-A1 | Propionic acid derivatives | URBAHNS KLAUS (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1328508-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | Bayer Aktiengesellschaft (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
| WO-2002028821-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187041-A1 | Propionic acid derivatives | PPARA, PPARD, PPARG | PPARA 1/4885HPGD 160/4885PPARG 3/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARA 2/4885HPGD 173/4885PPARG 3/4885 |
| US-20040176445-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARA 2/4885HPGD 173/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.